Evicenter
Taltz (ixekizumab) in Plaque psoriasis
Manufacturer
Eli Lilly and Company
Prescribing information
Taltz (opens in a new tab)
Questions
33
Last updated

All questions

Safety: Taltz (ixekizumab) in plaque psoriasis

8 questions · 2 sources

Side effects

What are the most common side effects of Taltz for plaque psoriasis?

Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Does Taltz cause yeast infections (candidiasis)?

Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Note: The last passage lists postmarketing reports from the Prescribing Information.

Can Taltz cause low white blood cell or platelet counts?

Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Does Taltz cause anti-drug antibodies in plaque psoriasis?

Safety evidence

What are the long-term side effects of Taltz for plaque psoriasis?

Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

“ADVERSE EVENTS OF SPECIAL INTEREST: INCIDENCE RATES PER 100 PYS Table Description Total PY=17,599 Year 1 PY=5688 Year 2 PY=3390 Year 3 PY=3108 (n) Year 4 PY=2882 (n) Year 5 PY=2375 (n) Serious infections 1.3 1.3 1.4 1.7 1.4 1.3 Candida infections 1.9 3.2 2.2 2.1 2.3 2.0 Hypersensitivity (non-anaphylaxis) 5.1 9.8 5.0 4.4 4.2 3.5 Hypersensitivity (potential anaphylaxis**) 0.1 0.2 0.1 0.0 (0) 0.0 (0) 0.0 (0) Crohn's disease†† 0.1 0.1 0.1 0.0 (1) 0.0 (1) 0.1 Ulcerative colitis†† 0.1 0.2 0.1 0.0 (1) 0.0 (0) 0.1 Malignancy-related (Nonmelanoma skin cancer) 0.3 0.5 0.2 0.4 0.2 0.2 Malignancy-related (Malignancies excluding NMSCs) 0.5 0.5 0.6 0.5 0.6 0.6 Injection site reactions 5.5 16.1 4.2 2.2 2.3 1.7 **After review of potential cases, no confirmed cases of anaphylaxis in clinical trials.10 ††Data on all suspected IBD, as identified by events potentially indicative of ulcerative colitis or Crohn’s disease, were adjudicated according to EPIMAD criteria by an external clinical review committee of gastroenterologists with IBD expertise. When incidence rates equal 0.0, the n value is added; n=number of events. The average and median Taltz exposure durations were 996.7 days and 718 days, respectively.11 Certain adverse events, such as malignancy, require longer observation periods and larger patient exposure to ascertain risk. In the reported safety population of the psoriasis clinical trials, not all patients received the recommended dosing regimen consistent with the FDA-approved label. PY=patient-year; NMSC=nonmelanoma skin cancer; IBD=inflammatory bowel disease; EPIMAD=Registre Epidemiologique des Maladies de l’Appareil Digestif.” (opens the source at this quote in a new tab)

Note: The table gives incidence rates per 100 patient-years for the total exposure period and then for Years 1 through 5, in the order of the header lines. Above the table, the Taltz HCP adult psoriasis page describes the pooled population as more than 6,800 patients across 15 clinical trials; its safety summary on the same page describes the long-term safety data as an integrated data set of 17 phase 1, 2, 3, and 4 studies in adults with moderate to severe plaque psoriasis, with a March 2022 cutoff.

Warnings

Does Taltz increase the risk of infections?

Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Can Taltz cause Crohn's disease or ulcerative colitis (IBD)?

Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Administration reactions

How common are injection site reactions with Taltz?

Applies to Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Note: The 17% and 3% rates are for Taltz 80 mg every 2 weeks and placebo through Week 12 in adults with moderate-to-severe plaque psoriasis, as presented on the Taltz HCP adult psoriasis page.